The debate over which dual antiplatelet therapy is best for diabetic CAD patients might favor generic prasugrel over ticagrelor (AstraZeneca’s Brilinta), after the TUXEDO-2 trial demonstrated that ticagrelor isn’t equivalent to prasugrel in this complex patient group.
- Both ticagrelor and prasugrel are potent P2Y12 inhibitors recommended after PCI, yet the optimal DAPT choice for diabetic patients was undefined.
- Diabetes increases both clotting and bleeding risks, so small differences between antiplatelet drugs can affect patient outcomes.
The TUXEDO-2 trial enrolled 1.8k participants across 66 clinical sites in India and randomized patients undergoing PCI to receive either ticagrelor or prasugrel plus aspirin in an open-label study design and found that…
- The trial’s primary composite endpoint (death, nonfatal MI, stroke, or major bleeding) occurred in 16.6% with ticagrelor versus 14.2% with prasugrel, failing the 5% noninferiority threshold.
- Ticagrelor showed numerically higher (but not statistically significant) rates of the death/MI/stroke composite (10.43% vs 8.63%) and major bleeding (8.41% vs 7.14%).
- The trial enrolled a particularly high-risk group since 85% had triple-vessel disease and nearly 25% required insulin.
Even though both are potent P2Y12 inhibitors, tricagrelor’s inability to demonstrate noninferiority indicates that meaningful clinical differences may exist in high-risk patients with diabetes and extensive coronary disease.
- For example, while the differences weren’t statistically significant on their own, prasugrel showed a steady advantage across outcomes.
- This implies that the noninferiority result may represent a real effect and not just statistical noise.
- The 2.33% absolute difference in the composite outcome also represents a clinically meaningful risk when applied across the large diabetic PCI population globally.
So what does this mean for DAPT in diabetic patients post-PCI?
- While guidelines group strong P2Y12 drugs together, the TUXEDO-2 study suggests prasugrel may be the better choice for patients with diabetes and multivessel CAD.
The Takeaway
Oftentimes, when a newer drug is compared to an older one in the same drug class, studies focus on larger, more common patient groups to prove noninferiority. While that is a practical way to evaluate treatments, this study reminds us that more complex, smaller patient groups sometimes need a second look.
